All In Biotech

Drug Trial Radar · NCT03516305

Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers

A Phase 1 Open-Label, Non-Randomized, Single-Dose, Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smoker Versus Non-Smoker Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Apr 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Apr 6, 2018

Primary completion

Aug 1, 2018

Study completion Aug 1, 2018

Sponsor

Lead sponsor
Engage Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Clinilabs, Inc.
First posted
May 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, non-randomized, single dose, pharmacokinetic study in 36 healthy adult male and female volunteers, including 18 smokers and 18 non-smokers. All subjects will be administered a single inhaled dose of Staccato alprazolam 1 mg via hand-held inhaler. Blood samples will be drawn for pharmacokinetic analysis. Eligible subjects are admitted to Phase 1 unit for up to 48 hours. Subjects will receive a post-study safety phone call 14 days(± 2 days) after dosing.

Conditions

  • Healthy

Interventions

  • Staccato Alprazolam 1 mgDrug

    alprazolam I mg administered via the Staccato hand-held inhaler device system.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) : Maximum observer drug concentration (Cmax)Time frame: Sequential time points : pre-dose, and at 2, 5, 10 and 30 minutes, and at 1, 2, 4, 6, 12, 24 and 36 hours post-dose.
  2. PK: Area under the concentration versus time curve (AUC)from Zero to Infinity (AUC[0-∞]Time frame: Sequential time points : pre-dose, and at 2, 5, 10 and 30 minutes, and at 1, 2, 4, 6, 12, 24 and 36 hours post-dose.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinilabs Research Unit

    Eatontown, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.